vimarsana.com

Page 11 - தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Han liangUnited statesHong kongInnovent biologicsBaorui liuQin xuZhiming liEli lillyXiubao renAdimab incyteJundong liNeoadjuvant resectableXiaofeng chenYi baCaicun zhouJin li

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Han liangUnited statesHong kongInnovent biologicsBaorui liuQin xuZhiming liEli lillyXiubao renAdimab incyteJundong liNeoadjuvant resectableXiaofeng chenYi baCaicun zhouJin li

Fierce Pharma Asia—BeiGene touts Q1, PARP inhibitor nod; Astellas culls muscle disease pact

BeiGene, Astellas and CANbridge made our news this week. (Google) BeiGene s first-quarter sales jumped 104% year over year to $106 million as it started to benefit from demand surging on new national reimbursement coverage. The Chinese biotech also won a local go-ahead for a PARP inhibitor to challenge incumbents Lynparza and Zejula. Astellas walked away from a muscle disease pact with Cytokinetics after a midstage trial flop. And more. BeiGene more than doubled product sales year over year to $106 million in the first quarter. The company’s PD-1 inhibitor tislelizumab, BTK inhibitor Brukinsa and Amgen-shared bone drug Xgeva enjoyed huge increases in patient demand following their inclusion on China’s National Reimbursement Drug List starting this March, which the company said more than offset the effect from price cuts. But the marketing suspension of a Bristol Myers Squibb chemo drug, Abraxane, remains a drag.

United statesGlaxosmithkline zejulaPurdue pharmaZai labAssociated pressDeutsche bankChina national reimbursement drug listBristol myers squibbCanbridge pharmaceuticalsNational reimbursement drug listLogicbio therapeuticGreater chinaஒன்றுபட்டது மாநிலங்களில்பர்‌ட்யூ பார்மாஜா ஆய்வகம்தொடர்புடையது ப்ரெஸ்

Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

- Toripalimab data will also be featured in ASCO's official press program -SHANGHAI, China, and REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences"

United statesPatricia keeganJunshi bioscienceEli lillyMcdavid stilwellDenise powellJunshi biosciencesCoherus biosciencesExchange commission onCoherus biosciences incShanghai junshi biosciences co ltdCommittee on foreign investmentPr teamAbbvie incInstitute of microbiology chinese academy scienceIr team

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

June 3, 2021, 5:00 p.m. Eastern Daylight Time “We are excited that results of JUPITER-02, a Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, have been selected for presentation during ASCO’s plenary session, which traditionally features high-impact studies,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited.” In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer and hepatobiliary mal

United statesSan franciscoPatricia keeganJunshi bioscienceEli lillyMcdavid stilwellDenise powellJunshi biosciencesCoherus biosciencesInstitute of microbiology chinese academy scienceIr teamCoherus biosciences incDrug administrationGenentech incShanghai junshi biosciences co ltdExchange commission

vimarsana © 2020. All Rights Reserved.